In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Fate Therapeutics, Inc. has reported that it raised $9.2 million in equity. The San Diego, California-based company is developing stem-cell modulators that guide the “fate” of non-embryonic stem cells as they mature thus enhancing their “homing” and proliferation for cancer patients undergoing stem-cell transplants. The company is developing other pipeline products for use in patients with cardiovascular disease, type 1 diabetes and muscle-wasting disorders. See North County Times, August 23, 2012.